This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendoza, J.-A.
Right arrow Articles by Favre, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendoza, J.-A.
Right arrow Articles by Favre, M.

 Previous Article  |  Next Article 

Journal of Virology, December 2006, p. 12420-12424, Vol. 80, No. 24
0022-538X/06/$08.00+0     doi:10.1128/JVI.02576-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Human Papillomavirus Type 5 E6 Oncoprotein Represses the Transforming Growth Factor ß Signaling Pathway by Binding to SMAD3{triangledown}

Jose-Andres Mendoza,1,2 Yves Jacob,1 Patricia Cassonnet,1 and Michel Favre1*

Unité postulante de Génétique, Papillomavirus et Cancer Humain, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex, France,1 Departamento de Microbiología y Parasitología Clínicas, Facultad de Medicina, Universidad de Los Andes, Av. Bolívar con calle Unda, Mérida 5101, Venezuela2

Received 12 December 2005/ Accepted 27 September 2006

Mechanisms of cellular transformation associated with human papillomavirus type 5 (HPV5), which is responsible for skin carcinomas in epidermodysplasia verruciformis (EV) patients, are poorly understood. Using a yeast two-hybrid screening and molecular and cellular biology experiments, we found that HPV5 oncoprotein E6 interacts with SMAD3, a key component in the transforming growth factor ß1 (TGF-ß1) signaling pathway. HPV5 E6 inhibits SMAD3 transactivation by destabilizing the SMAD3/SMAD4 complex and inducing the degradation of both proteins. Interestingly, the E6 protein of nononcogenic EV HPV9 failed to interact with SMAD3, suggesting that downregulation of the TGF-ß1 signaling pathway could be a determinant in HPV5 skin carcinogenesis.

* Corresponding author. Mailing address: Unité postulante de Génétique, Papillomavirus et Cancer Humain, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex, France. Phone: 33-1-45-68-87-45. Fax: 33-1-45-68-89-66. E-mail: mfavre{at}pasteur.fr.

{triangledown} Published ahead of print on 4 October 2006.

Journal of Virology, December 2006, p. 12420-12424, Vol. 80, No. 24
0022-538X/06/$08.00+0     doi:10.1128/JVI.02576-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lazarczyk, M., Cassonnet, P., Pons, C., Jacob, Y., Favre, M. (2009). The EVER Proteins as a Natural Barrier against Papillomaviruses: a New Insight into the Pathogenesis of Human Papillomavirus Infections. Microbiol. Mol. Biol. Rev. 73: 348-370 [Abstract] [Full Text]  
  • Lazarczyk, M., Pons, C., Mendoza, J.-A., Cassonnet, P., Jacob, Y., Favre, M. (2008). Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. JEM 205: 35-42 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»